Keywords: Antivirals, Market uptake, China, South Korea, Cost, Reimburesemnt, Roche, Pagasys, Merck & Co, Pegintron, Incivek, Victrelis, Decision Resources
Uptake of Peg-IFN agents for HCV in China and South Korea hindered by relatively high cost and their partial reimbursement status
Article | 21 October 2012
Although pegylated interferon (peg-IFN; Roche’s Pegasys, Merck & Co’s PegIntron) combined with ribavirin is recommended as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
